Toronto, ON, Aug. 07, 2025 (GLOBE NEWSWIRE) — The Toronto Downtown West BIA (TDWBIA), in partnership with the City of Toronto, is pleased to announce initial improvements to Clarence Square Park – a widely-accessed green space in the downtown core and a key pedestrian and cycling route. Enhancements include tree trimming, landscaping, 300 square metres […]
(NasdaqGM:YMAB), PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on Friday, August 8,
(NASDAQ:KELYA),(NASDAQ:KELYB), TROY, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a leading global specialty talent solutions provider, today announced that Chris Layden has been selected to serve as president and chief executive officer, effective September 2, 2025. Layden will succeed Peter Quigley, who previously announced his intent to retire as president and
(NasdaqGM:NTLA), Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projections; Tracking to enroll at least 650 patients cumulatively by year-end Expanding total enrollment of the MAGNITUDE study to approximately 1,200 patients, subject to health authority review, with no expected impact on
(TSX:GUD), Achieved record-high quarterly revenues since inceptionIncreased 2025 financial guidance MONTREAL, Aug. 07, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2025. All currency amounts are in thousands except for share and per
(NASDAQ:SAVA), Joseph Hulihan, MD, MSHP, brings substantial clinical development experience advancing novel therapies for TSC-related epilepsy and other neurological disorders Clinical study for simufilam in TSC-related epilepsy expected to begin in H1 2026 AUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on
(NASDAQ:COLL), – Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM(R) Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in
(NASDAQ:BDTX), Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025 Exploring partnership opportunities to advance pivotal development of silevertinib in NSCLC and GBM Plan to meet with FDA regarding 1L NSCLC development path in 1H 2026,
(NasdaqGM:MTSI), LOWELL, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) — MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI), a leading supplier of semiconductor products, today announced its financial results for its fiscal third quarter ended July 4, 2025. Third Quarter Fiscal Year 2025 GAAP Results Revenue was $252.1 million, an increase of 32.3%, compared to $190.5
(NASDAQ:IFRX), INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025 Phase 1/2 data announced by Staidson BioPharmaceuticals for InflaRx-partnered C5a antibody BDB-001 in ANCA-associated vasculitis (AAV) were favorable, with Staidson expecting Phase 3 study initiation InflaRx working diligently toward unblinding of